present disclosure relates to methods for relaxing airway smooth muscle tissue, alleviating or preventing bronchospasm, and treating lung diseases by administering an HMG-CoA reductase inhibitor (statin) directly to lung tissue by inhalation. The disclosure also relates to formulations and compositions useful for the practice of methods of the disclosure.

present disclosure relates to methods for relaxing airway smooth muscle tissue, alleviating or preventing bronchospasm, and treating lung diseases by administering an HMG-CoA reductase inhibitor (statin) directly to lung tissue by inhalation. The disclosure also relates to formulations and compositions useful for the practice of methods of the disclosure.

A portable medicament case that includes a medicament provided in a package, and first and second housing members that are configured to form a medicament package receiving cavity when joined together. Each housing member including a mating member that is configured for engagement with the other housing member in order to join the first and second housing members together in a sealed configuration that prevents moisture or contaminants from entering into the cavity. Also, a magazine containing a plurality of medicament cases for administration of medicaments to a group of people, and a method of administering medications to mass casualties of multiple persons that are in need thereof. The medicaments are rapidly disintegratable and can include a dye that stains the person's mouth so that medical personnel can determine who has been treated with the medicament.

A portable medicament case that includes a medicament provided in a package, and first and second housing members that are configured to form a medicament package receiving cavity when joined together. Each housing member including a mating member that is configured for engagement with the other housing member in order to join the first and second housing members together in a sealed configuration that prevents moisture or contaminants from entering into the cavity. Also, a magazine containing a plurality of medicament cases for administration of medicaments to a group of people, and a method of administering medications to mass casualties of multiple persons that are in need thereof. The medicaments are rapidly disintegratable and can include a dye that stains the person's mouth so that medical personnel can determine who has been treated with the medicament.

A beverage comprising water, phycocyanin and having a heavy metals content below a threshold amount, the beverage having a pH within a certain range and a minimum acceptable shelf life, by optimizing the steps in the production of the beverage, but without adding many chemical substances and without carrying out harsh chemical treatment on the natural substances. By the combined use of a phycocyanin obtained, for example, by ultrafiltration or by treatment under pressure, with sterile demineralized water, and mixing the other components separately from the bacteria and other contaminants, in an aseptic environment, it is possible to provide a beverage that has nutraceutical effects, with low heavy metals content, at a suitable pH, and with an extended shelf life.

A beverage comprising water, phycocyanin and having a heavy metals content below a threshold amount, the beverage having a pH within a certain range and a minimum acceptable shelf life, by optimizing the steps in the production of the beverage, but without adding many chemical substances and without carrying out harsh chemical treatment on the natural substances. By the combined use of a phycocyanin obtained, for example, by ultrafiltration or by treatment under pressure, with sterile demineralized water, and mixing the other components separately from the bacteria and other contaminants, in an aseptic environment, it is possible to provide a beverage that has nutraceutical effects, with low heavy metals content, at a suitable pH, and with an extended shelf life.

New host-protective molecules containing conjugated triene and diene double bonds with each carrying a 13-carbon position alcohol and were derived from n-3 docosapentaenoic acid (DPA, C22:5) were produced in neutrophil-endothelial co-cultures, and they are present in human and mouse tissues after sterile inflammation or infection. These compounds, termed 13-series resolvins (RvT), demonstrated potent protective actions increasing mice survival during Escherichia coli infections. Their biosynthesis during neutrophil-endothelial cell interactions was initiated by endothelial cyclooxygenase-2 (COX-2) and increased by atorvastatin via S-nitrosylation of COX-2. Atorvastatin and RvT were additive in E. coli infections in mice where they accelerated resolution of inflammation and increased survival >60%. Results documented novel host protective molecules in bacterial infections, namely RvT, derived from n-3 DPA via transcellular biosynthesis and increased by atorvastatin. RvT also regulated human and mouse phagocyte responses stimulating bacterial phagocytosis and regulating inflammasome components to regulate key innate protective responses in the resolution of infectious-inflammation.

New host-protective molecules containing conjugated triene and diene double bonds with each carrying a 13-carbon position alcohol and were derived from n-3 docosapentaenoic acid (DPA, C22:5) were produced in neutrophil-endothelial co-cultures, and they are present in human and mouse tissues after sterile inflammation or infection. These compounds, termed 13-series resolvins (RvT), demonstrated potent protective actions increasing mice survival during Escherichia coli infections. Their biosynthesis during neutrophil-endothelial cell interactions was initiated by endothelial cyclooxygenase-2 (COX-2) and increased by atorvastatin via S-nitrosylation of COX-2. Atorvastatin and RvT were additive in E. coli infections in mice where they accelerated resolution of inflammation and increased survival >60%. Results documented novel host protective molecules in bacterial infections, namely RvT, derived from n-3 DPA via transcellular biosynthesis and increased by atorvastatin. RvT also regulated human and mouse phagocyte responses stimulating bacterial phagocytosis and regulating inflammasome components to regulate key innate protective responses in the resolution of infectious-inflammation.

The disclosure provides compositions, methods, and devices for use in delivering Mitomycin-C(MMC), an antineoplastic chemotherapy drug often used for bladder instillations to treat bladder cancer, which degrades in both acidic and alkaline environments. The disclosure provides a solution of buffered MMC (or a different drug) in 50% propylene glycol that maintains a pH from 7.0 to 8.0 when introduced into acidic solutions (pH of 5.0) and is stable when stored at 2-8° C. for greater than 134 days. This formulation can be produced in an FDA registered 503B Outsourcing facility in a pre-filled, ready-to-administer syringe kit with pre-attached closed system transfer device and accessories required for bladder instillation.

It has been established that CD55 expression on human mesenchymal stem cells (hMSCs) is positively correlated with successful allogenic transplantation procedures. Compositions and methods for improved hMSCs, having increased expression of CD55 mRNA and/or increased expression of CD55 on the surface of the cell as compared to a control cell, are provided. Methods include isolating hMSCs from a tissue that naturally has increased CD55 expression, such as adipose tissue derived hMSC (AT-hMSC); and/or in vitro culturing hMSCs in the presence of one or more active agents that stimulates or enhances the expression of CD55 mRNA, and/or increases the surface expression of CD55 in the hMSC to provide improved hMSCs. Preferred active agents include HMG-CoA reductase inhibitors such as atorvastatin and EGFR inhibitors such as erlotinib. Compositions and methods for administering the improved hMSCs to a subject in need thereof are also provided.